Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

Reda E. Girgis, Stephen Mathai, Jerry A. Krishnan, Fredrick Wigley, Paul M Hassoun

Research output: Contribution to journalArticle

Abstract

Background: Bosentan improves clinical outcomes in pulmonary arterial hypertension (PAH), particularly in the idiopathic (IPAH) subset. Scant data are available regarding PAH associated with the scleroderma spectrum of diseases (APAH-SSD). Here we review our experience with bosentan in these 2 groups. Methods: Included were all patients at our center with either IPAH or APAH-SSD in whom bosentan was the first-line, single-agent therapy with at least 6 months of follow-up. Changes in the World Health Organization (WHO) functional class from baseline to the most recent follow-up on monotherapy were compared between the 2 groups, as well as overall survival and time to a composite end point of hepatotoxicity requiring discontinuation, use of additional therapy, or death. Results: Nineteen IPAH and 17 APAH-SSD subjects with similar baseline clinical characteristics and a median follow-up 9 months (range, 6-44) were analyzed. In IPAH subjects, WHO class improved from 3.1 ± 0.5 at baseline to 2.4 ± 0.8 (p = 0.005). No change occurred in the APAH-SSD group: 2.9 ± 0.3 vs. 2.8 ± 0.8; p = 0.5. Hepatotoxicity requiring discontinuation developed in 6 patients (17%). Seven (37%) IPAH and 8 SSD patients (47%) reached the composite end point (p = NS). Overall survival at 1 and 2 years was 100% and 100% vs 87% and 79% for IPAH and APAH-SSD patients, respectively (p = 0.075). Conclusions: First-line bosentan monotherapy is associated with long-term improvement in functional class and good overall survival in patients with WHO class III IPAH. Most APAH-SSD patients experienced stability or decline in functional class and tended to have a higher mortality.

Original languageEnglish (US)
Pages (from-to)1626-1631
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume24
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Pulmonary Hypertension
Survival
Silver Sulfadiazine
Familial Primary Pulmonary Hypertension
bosentan
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

@article{c85f6e2336864465884cb88d4cfd54f3,
title = "Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases",
abstract = "Background: Bosentan improves clinical outcomes in pulmonary arterial hypertension (PAH), particularly in the idiopathic (IPAH) subset. Scant data are available regarding PAH associated with the scleroderma spectrum of diseases (APAH-SSD). Here we review our experience with bosentan in these 2 groups. Methods: Included were all patients at our center with either IPAH or APAH-SSD in whom bosentan was the first-line, single-agent therapy with at least 6 months of follow-up. Changes in the World Health Organization (WHO) functional class from baseline to the most recent follow-up on monotherapy were compared between the 2 groups, as well as overall survival and time to a composite end point of hepatotoxicity requiring discontinuation, use of additional therapy, or death. Results: Nineteen IPAH and 17 APAH-SSD subjects with similar baseline clinical characteristics and a median follow-up 9 months (range, 6-44) were analyzed. In IPAH subjects, WHO class improved from 3.1 ± 0.5 at baseline to 2.4 ± 0.8 (p = 0.005). No change occurred in the APAH-SSD group: 2.9 ± 0.3 vs. 2.8 ± 0.8; p = 0.5. Hepatotoxicity requiring discontinuation developed in 6 patients (17{\%}). Seven (37{\%}) IPAH and 8 SSD patients (47{\%}) reached the composite end point (p = NS). Overall survival at 1 and 2 years was 100{\%} and 100{\%} vs 87{\%} and 79{\%} for IPAH and APAH-SSD patients, respectively (p = 0.075). Conclusions: First-line bosentan monotherapy is associated with long-term improvement in functional class and good overall survival in patients with WHO class III IPAH. Most APAH-SSD patients experienced stability or decline in functional class and tended to have a higher mortality.",
author = "Girgis, {Reda E.} and Stephen Mathai and Krishnan, {Jerry A.} and Fredrick Wigley and Hassoun, {Paul M}",
year = "2005",
month = "10",
doi = "10.1016/j.healun.2004.12.113",
language = "English (US)",
volume = "24",
pages = "1626--1631",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

AU - Girgis, Reda E.

AU - Mathai, Stephen

AU - Krishnan, Jerry A.

AU - Wigley, Fredrick

AU - Hassoun, Paul M

PY - 2005/10

Y1 - 2005/10

N2 - Background: Bosentan improves clinical outcomes in pulmonary arterial hypertension (PAH), particularly in the idiopathic (IPAH) subset. Scant data are available regarding PAH associated with the scleroderma spectrum of diseases (APAH-SSD). Here we review our experience with bosentan in these 2 groups. Methods: Included were all patients at our center with either IPAH or APAH-SSD in whom bosentan was the first-line, single-agent therapy with at least 6 months of follow-up. Changes in the World Health Organization (WHO) functional class from baseline to the most recent follow-up on monotherapy were compared between the 2 groups, as well as overall survival and time to a composite end point of hepatotoxicity requiring discontinuation, use of additional therapy, or death. Results: Nineteen IPAH and 17 APAH-SSD subjects with similar baseline clinical characteristics and a median follow-up 9 months (range, 6-44) were analyzed. In IPAH subjects, WHO class improved from 3.1 ± 0.5 at baseline to 2.4 ± 0.8 (p = 0.005). No change occurred in the APAH-SSD group: 2.9 ± 0.3 vs. 2.8 ± 0.8; p = 0.5. Hepatotoxicity requiring discontinuation developed in 6 patients (17%). Seven (37%) IPAH and 8 SSD patients (47%) reached the composite end point (p = NS). Overall survival at 1 and 2 years was 100% and 100% vs 87% and 79% for IPAH and APAH-SSD patients, respectively (p = 0.075). Conclusions: First-line bosentan monotherapy is associated with long-term improvement in functional class and good overall survival in patients with WHO class III IPAH. Most APAH-SSD patients experienced stability or decline in functional class and tended to have a higher mortality.

AB - Background: Bosentan improves clinical outcomes in pulmonary arterial hypertension (PAH), particularly in the idiopathic (IPAH) subset. Scant data are available regarding PAH associated with the scleroderma spectrum of diseases (APAH-SSD). Here we review our experience with bosentan in these 2 groups. Methods: Included were all patients at our center with either IPAH or APAH-SSD in whom bosentan was the first-line, single-agent therapy with at least 6 months of follow-up. Changes in the World Health Organization (WHO) functional class from baseline to the most recent follow-up on monotherapy were compared between the 2 groups, as well as overall survival and time to a composite end point of hepatotoxicity requiring discontinuation, use of additional therapy, or death. Results: Nineteen IPAH and 17 APAH-SSD subjects with similar baseline clinical characteristics and a median follow-up 9 months (range, 6-44) were analyzed. In IPAH subjects, WHO class improved from 3.1 ± 0.5 at baseline to 2.4 ± 0.8 (p = 0.005). No change occurred in the APAH-SSD group: 2.9 ± 0.3 vs. 2.8 ± 0.8; p = 0.5. Hepatotoxicity requiring discontinuation developed in 6 patients (17%). Seven (37%) IPAH and 8 SSD patients (47%) reached the composite end point (p = NS). Overall survival at 1 and 2 years was 100% and 100% vs 87% and 79% for IPAH and APAH-SSD patients, respectively (p = 0.075). Conclusions: First-line bosentan monotherapy is associated with long-term improvement in functional class and good overall survival in patients with WHO class III IPAH. Most APAH-SSD patients experienced stability or decline in functional class and tended to have a higher mortality.

UR - http://www.scopus.com/inward/record.url?scp=25844531004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844531004&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2004.12.113

DO - 10.1016/j.healun.2004.12.113

M3 - Article

C2 - 16210140

AN - SCOPUS:25844531004

VL - 24

SP - 1626

EP - 1631

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 10

ER -